A potential treatment for heart attack and stroke derived from spider venom has been administered to the first participants in clinical trial. A team of researchers from the University of Queensland, Australia published preclinical analysis showing the protein Hi1a could treat heart attack and stroke patients. The… Read More
A new study from researchers at Lund University in Sweden and Imperial College London suggests that treating patients earlier with a combination of statins and the cholesterol-lowering drug ezetimibe could prevent thousands of new heart attacks. For those who survive a heart attack, the risk of a… Read More
A project to develop a drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF). Professor Glenn King from the University of Queensland’s (UQ) Institute for Molecular Bioscience… Read More
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering from heart attacks or stroke. The GLP-1 receptor agonist is already approved for use in the treatment of obesity… Read More
Ethris and Heqet Therapeutics have revealed plans to collaborate on RNA-based therapeutics for heart attack and heart failure, using non coding RNAs (ncRNAs) in regenerating heart tissue. Under the terms of the agreement, Heqet Therapeutics will lead the development of the programme, while Ethris will provide… Read More
DDW’s Reece Armstrong speaks to Hendrik Streefkerk, Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases. Based in France, CellProthera is a small, regenerative cell… Read More
Serca Pharmaceuticals, a cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, has presented data on a novel approach to modulate the beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that… Read More
A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK under a new agreement. The Phase IIb LIBERATE study will test the tolerance and the efficacy of glenzocimab 1000mg to reduce heart damage following a myocardial infarction (MI). Read More
A drug candidate for heart attacks which contains venom from a deadly spider has moved closer to clinical trials due to investment of $23 million. A research team at the University of Queensland have developed a potential therapy for heart attacks and stroke which uses a molecule… Read More
